Information
Dr. Reddy’s Laboratories reported a steep decline in earnings for the quarter ended March 31, 2026, as decrease gross sales of key merchandise in North America and a one-time inventory-related adjustment weighed closely on profitability.
Dr. Reddy’s This fall Outcomes: Revenue Slumps 86%, Income Drops as North America Enterprise Faces Sharp Strain
The pharmaceutical main posted a consolidated web revenue of Rs 221 crore within the fourth quarter of FY26, marking an 86% drop from Rs 1,587 crore reported within the corresponding quarter final 12 months. Income from operations additionally declined 12% year-on-year to Rs 7,516 crore, in contrast with Rs 8,506 crore in Q4FY25.
The March quarter numbers had been additionally weaker on a sequential foundation. Revenue after tax fell 81% from Rs 1,190 crore within the December quarter, whereas income slipped 14% from Rs 8,727 crore recorded in Q3FY26.
800% Last Dividend Payout! Dr Reddy’s Recommends, Verify Quantity & File Particulars
Alongside the outcomes, the board advisable a closing dividend of Rs 8 per share for FY26, which works out to 800% of the face worth of Re 1 per fairness share.
The dividend is topic to approval by shareholders on the upcoming Annual Common Assembly. The corporate has fastened July 10, 2026, because the document date to find out eligible shareholders.
Dr. Reddy’s This fall Earnings FY26 Hit by North America Weak point
The corporate’s efficiency was affected primarily by decrease volumes of Lenalidomide, one among its key oncology merchandise in the US, together with pricing stress in North America and European generics markets.
One-Time Rs 450 Crore Lenalidomide Shelf Inventory Adjustment Additional Weighed on
As well as, the corporate recorded a one-time Shelf Inventory Adjustment of Rs 450 crore associated to Lenalidomide, which considerably impacted reported income and margins in the course of the quarter.
After excluding this one-off adjustment, adjusted income for Q4FY26 stood at Rs 7,970 crore. On this foundation, income was down 6.3% in contrast with the year-ago interval and eight.7% decrease than the earlier quarter, indicating that underlying enterprise tendencies had been considerably extra steady than the headline numbers prompt.
Dr. Reddy’s Laboratories Full-12 months FY26 Income Grows Regardless of Quarterly Strain
Regardless of the weak March quarter, Dr Reddy’s reported modest development for the total monetary 12 months.
Income from operations for FY26 rose 3% to Rs 33,593 crore, in contrast with Rs 32,553 crore in FY25. Excluding the Shelf Inventory Adjustment, adjusted annual income stood at Rs 34,050 crore, reflecting a stronger 4.6% year-on-year enhance.
The corporate stated development was broad-based throughout most key geographies, with North America being the first space of weak point attributable to decrease Lenalidomide gross sales and the one-time stock adjustment.
Margins Contract Sharply in This fall
Gross margin for the March quarter declined to 44.8%, down 1,074 foundation factors from the identical interval final 12 months and 881 foundation factors from the December quarter.
The sharp drop was attributed to decreased contribution from Lenalidomide, continued worth erosion in developed markets and the one-time Shelf Inventory Adjustment.
For the total 12 months, gross margin stood at 52.8%, down 573 foundation factors from FY25.
Nevertheless, after adjusting for the Shelf Inventory Adjustment and a one-time provision linked to India’s new Labour Codes booked in Q3FY26, gross margin improved to 48% for Q4FY26 and 53.5% for FY26, suggesting that the underlying profitability development remained comparatively resilient.
Disclaimer: The views and suggestions expressed are solely these of the person analysts or entities and don’t replicate the views of Goodreturns.in or Greynium Data Applied sciences Non-public Restricted (collectively referred as “we”). We don’t assure, endorse or take duty for the accuracy, completeness or reliability of any content material, nor do we offer any funding recommendation or solicit the acquisition or sale of securities. All data is offered for informational and academic functions solely and needs to be independently verified from licensed monetary advisors earlier than making any funding selections.
